Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
Details for Australian Patent Application No. 2007325838 (hide)
International Classifications
Event Publications
18 June 2009 PCT application entered the National Phase
PCT publication WO2008/066752 Priority application(s): WO2008/066752
25 June 2009 Alteration of Name
The name of the applicant has been altered to Adnexus, a Bristol Myers Squibb R & D Company
13 August 2009 Corrigenda
Change of Names(s) of Applicant(s), Section 104 - 2007 Under the name Adnexus, a Bristol Myers Squibb R & D Company, Application No. 2007325838, under INID(71), correct the name to read Adnexus, a Bristol-Myers Squibb R&D Company
24 June 2010 Amendment Made
The nature of the amendment is as shown in the statement(s) filed 03 Jun 2010 2008
10 March 2011 Assignment before Grant
Adnexus, a Bristol-Myers Squibb R&D Company The application has been assigned to Bristol-Myers Squibb Company 2008
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2007325867-Personalization of video and sound presentation on a gaming machine
2007325836-Methods of treating mental retardation, Down's syndrome, fragile X syndrome and autism
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser
